JPH0359913B2 - - Google Patents

Info

Publication number
JPH0359913B2
JPH0359913B2 JP59102993A JP10299384A JPH0359913B2 JP H0359913 B2 JPH0359913 B2 JP H0359913B2 JP 59102993 A JP59102993 A JP 59102993A JP 10299384 A JP10299384 A JP 10299384A JP H0359913 B2 JPH0359913 B2 JP H0359913B2
Authority
JP
Japan
Prior art keywords
acid
dihydrodesoxyglyseolic
salt
culture
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59102993A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60246396A (ja
Inventor
Fumio Nakagawa
Yoshio Tsujita
Mitsuo Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to JP59102993A priority Critical patent/JPS60246396A/ja
Priority to CA000482074A priority patent/CA1252058A/en
Priority to EP85303628A priority patent/EP0162715B1/en
Priority to DE8585303628T priority patent/DE3570249D1/de
Priority to ES543407A priority patent/ES8609482A1/es
Priority to AT85303628T priority patent/ATE43140T1/de
Publication of JPS60246396A publication Critical patent/JPS60246396A/ja
Priority to US07/131,438 priority patent/US4822879A/en
Publication of JPH0359913B2 publication Critical patent/JPH0359913B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
JP59102993A 1984-05-22 1984-05-22 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類 Granted JPS60246396A (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP59102993A JPS60246396A (ja) 1984-05-22 1984-05-22 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
CA000482074A CA1252058A (en) 1984-05-22 1985-05-22 Enzyme-inhibitory griseolic acid derivatives, and their use
EP85303628A EP0162715B1 (en) 1984-05-22 1985-05-22 Enzyme-inhibitory griseolic acid derivatives, and their use
DE8585303628T DE3570249D1 (en) 1984-05-22 1985-05-22 Enzyme-inhibitory griseolic acid derivatives, and their use
ES543407A ES8609482A1 (es) 1984-05-22 1985-05-22 Un metodo para producir acido dihidrodesoxigriseolico y sa- les y esteres del mismo
AT85303628T ATE43140T1 (de) 1984-05-22 1985-05-22 Derivate von enzym-hemmender griseolsaeure und deren verwendung.
US07/131,438 US4822879A (en) 1984-05-22 1987-12-11 Enzyme-inhibitory griseolic acid derivatives, and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59102993A JPS60246396A (ja) 1984-05-22 1984-05-22 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類

Publications (2)

Publication Number Publication Date
JPS60246396A JPS60246396A (ja) 1985-12-06
JPH0359913B2 true JPH0359913B2 (enExample) 1991-09-12

Family

ID=14342217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59102993A Granted JPS60246396A (ja) 1984-05-22 1984-05-22 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類

Country Status (7)

Country Link
US (1) US4822879A (enExample)
EP (1) EP0162715B1 (enExample)
JP (1) JPS60246396A (enExample)
AT (1) ATE43140T1 (enExample)
CA (1) CA1252058A (enExample)
DE (1) DE3570249D1 (enExample)
ES (1) ES8609482A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6094992A (ja) * 1983-10-28 1985-05-28 Sankyo Co Ltd グリゼオ−ル酸誘導体
EP0319050B1 (en) 1985-04-19 1995-04-12 Sankyo Company Limited Griseolic acid derivatives, their preparation and their use
DK167878B1 (da) * 1985-04-19 1993-12-27 Sankyo Co Griseolsyrederivater
US5091431A (en) * 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US4971972A (en) * 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
NZ504436A (en) 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668695A (en) * 1979-11-10 1981-06-09 Sankyo Co Ltd Enzyme inhibitor griseolic acid and its preparation

Also Published As

Publication number Publication date
US4822879A (en) 1989-04-18
ES543407A0 (es) 1986-09-01
EP0162715B1 (en) 1989-05-17
DE3570249D1 (en) 1989-06-22
JPS60246396A (ja) 1985-12-06
EP0162715A2 (en) 1985-11-27
EP0162715A3 (en) 1987-08-26
CA1252058A (en) 1989-04-04
ES8609482A1 (es) 1986-09-01
ATE43140T1 (de) 1989-06-15

Similar Documents

Publication Publication Date Title
US4460765A (en) Enzyme inhibitor produced by cultivation of streptomyces microorganisms
JPH03187389A (ja) 新規な免疫抑制剤化合物
JP5671622B2 (ja) フルクトシル化プエラリンおよびその調製方法と用途
KR0145680B1 (ko) "류스트로덕신"으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도
JPH0359913B2 (enExample)
JP2863637B2 (ja) 新規なアミノオリゴ糖誘導体およびその製造方法
JPS5850999B2 (ja) ホ−テイマイシンａｅおよびその製造法
US4771070A (en) CL-1957A antibiotic compound
EP0156524B1 (en) 2'-chloropentostatin, a pharmaceutical composition comprising the compound and a novel microorganism for producing the compound
JPH0429356B2 (enExample)
JPH0633312B2 (ja) １４−ハイドロキシエリスロマイシン誘導体およびその製造方法
JP2695225B2 (ja) 新規物質ｕｃｔ−１００３
JPS6144841A (ja) １−ヒドロキシシトロジンおよびそれらの微生物学的製造法
PL205951B1 (pl) Pochodne kaloporozydu, sposób ich wytwarzania i ich zastosowanie, lek, sposób jego wytwarzania oraz mikroorganizm
AU665488B2 (en) New compound, leustroducsin H, its preparation and its therapeutic use
JPH0367077B2 (enExample)
JP2873341B2 (ja) 抗生物質ｔａｎ―９５０、その製造法および用途
JPH01216927A (ja) 抗腫瘍剤
JPH0149357B2 (enExample)
JPH07506332A (ja) 医薬としての複素環化合物のリン酸エステル
JPH07278055A (ja) 抗菌性物質ｂｅ−４０６６５類
JPS584796A (ja) 抗腫瘍性物質デオキシペンタレニルグルクロンおよびその製造法
JPS5836000B2 (ja) イソホ−テイマイシンａおよびその製造法
JPS626695B2 (enExample)
JPS63157992A (ja) 抗生物質ｎ−ヒドロキシジヒドロアビコビロマイシン